Canada · Delayed Price · Currency is CAD Medexus Pharmaceuticals Company Description
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States.
It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy.
The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication.
Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms.
The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018.
Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
| Country | Canada |
| Founded | 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 91 |
| CEO | Kenneth d'Entremont |
Contact Details
Address: 10 King Street East Toronto, ON ON Canada | |
| Phone | 877 422 5242 |
Stock Details
| Ticker Symbol | MDP |
| Exchange | Toronto Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| ISIN Number | CA58410Q2036 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kenneth d'Entremont | Chief Executive Officer and Director |
| Brendon Buschman | Chief Financial Officer |
| Richard Labelle | Chief Operating Officer |
| Ian C. Wildgoose Brown | General Counsel and Corporate Secretary |
| Tina Byers CFA | Executive of Investor Relations |
| Bill Poncy | Senior Vice President of Commercial Operations - United States |
| Brian Peters | Vice President of Sales and Marketing - United States |